Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 8Gastrointestinal 6Breast 6Genitourinary 3NET 2Endocrine 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1CNS 1

Conditions

Neuroendocrine Tumors 2

Interventions

lutetium Lu 177 dotatate 41Everolimus 38Magnetic Resonance Spectroscopy 18Temozolomide 17lanreotide 16gallium Ga 68 dotatate 15Octreotide 14pembrolizumab 13Nivolumab 13Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11surufatinib 9pasireotide 9Sunitinib 9Specimen Handling 9Positron Emission Tomography Computed Tomography 93-Iodobenzylguanidine 9Lutetium-177 8Carboplatin 8amino-acid, glucose, and electrolyte solution 6Ipilimumab 6Ga(III)-DOTATOC 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6lenvatinib 5copper dotatate CU-64 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Liquid Biopsy × NET × Clear all
NCT05255133 2025-01-06

Liquid-NET

Universiteit Antwerpen

Phase NA Completed
22 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05268952 2022-03-07

A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0)

University Hospital, Antwerp

Phase NA Unknown
100 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡